We have located links that may give you full text access.
Journal Article
Review
European Society for Vascular Surgery (ESVS) AAA Guidelines Focused Update on patients treated with the Nellix EndoVascular Aneurysm Sealing (EVAS) system.
European Journal of Vascular and Endovascular Surgery 2023 January 7
OBJECTIVE: To provide guidance on the surveillance and management of patients treated with Endovascular Aneurysm Seal (EVAS).
METHOD: Based on a scoping review of risk for late serious aortic-related adverse events in patients treated with EVAS for AAA, the European Society for Vascular Surgery (ESVS) AAA Clinical Practice Guidelines Writing Committee agreed on recommendations graded according to the European Society of Cardiology (ESC) grading system.
RESULTS: EVAS has a very high incidence of late endograft migration resulting in proximal type 1 endoleak with risk of rupture, requiring open conversion with device explant. The reported mortality for elective explantation varies between 0% and 14%, while acute conversion for rupture has a very dismal prognosis with 67-75% mortality.
CONCLUSION: It is recommended that all patients in whom a Nellix device has been implanted should be identified, properly informed and enrolled in enhanced surveillance. If device failure is detected, early elective device explant should be considered in surgically fit patients.
METHOD: Based on a scoping review of risk for late serious aortic-related adverse events in patients treated with EVAS for AAA, the European Society for Vascular Surgery (ESVS) AAA Clinical Practice Guidelines Writing Committee agreed on recommendations graded according to the European Society of Cardiology (ESC) grading system.
RESULTS: EVAS has a very high incidence of late endograft migration resulting in proximal type 1 endoleak with risk of rupture, requiring open conversion with device explant. The reported mortality for elective explantation varies between 0% and 14%, while acute conversion for rupture has a very dismal prognosis with 67-75% mortality.
CONCLUSION: It is recommended that all patients in whom a Nellix device has been implanted should be identified, properly informed and enrolled in enhanced surveillance. If device failure is detected, early elective device explant should be considered in surgically fit patients.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app